Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance
Launched by STANFORD UNIVERSITY · Jan 11, 2021
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Previous studies have found convincing evidence of the relationship between insulin resistance, T cell profiles, macrophage profiles and inflammation of the fat cells. This study will add human subjects to that body of evidence.
Overview Aim 1: Test the hypothesis that the balance of anti- inflammatory vs proinflammatory T cells is protective for systemic insulin resistance. T cell profiles in subcutaneous and visceral tissue and blood will be compared in IR vs IS obese humans at baseline and potentially after 12 months following weight loss. Tcell profile will be evaluated for relationshi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Current patients of Stanford Healthcare, Bariatric Surgery Clinic, scheduled to undergo bariatric surgery (sleeve or RYGB)
- • BMI 30-55kg/m2
- • 30-65 years of age
- • good general health, no major organ disease
- • non-diabetic by current American Diabetes Association (ADA) criteria (fasting glucose \<126mg/dl)
- Exclusion Criteria:
- • Subjects with any clinical or biochemical evidence of significant anemia, gastrointestinal, cardiac, hepatic or renal disease will be excluded.
- • Subjects with other medical problems may participate as long as the problems are stable.
- • Subjects with active psychiatric disorders or past history of bariatric surgery
- • Pregnant or lactating women will also be excluded from the study, due to possible risk to the fetus or infant.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Tracey McLaughlin, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials